Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mulberry total alkaloid tablets versus sitagliptin for weight reduction in obese adults with type 2 diabetes
ChiCTR2300078414Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Dec 2023
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mulberry total alkaloid tablet and sitagliptin in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Body mass index. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
mulberry total alkaloid tabletsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2300078414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078414.